NextGen Heme Summit

DENVER 2026

A highly curated forum uniting today’s leaders and the next generation in hematologic malignancies.
Register InterestDownload Prospectus

Date

August 27-28, 2026

Location

Denver, Colorado

Focus

Leukemias, MDS and MPN

Event Overview

We are honored to host an exclusive forum from August 27th to 28th in Denver, Colorado led by Dr. Elias Jabbour and Dr. Naval  Daver. This two-day meeting will bring together established  leaders and the next generation of rising voices in oncologic  hematology for a rare opportunity to exchange ideas, forge  meaningful connections, and chart the future of science and  leadership in the field.
With a focus on leukemias, lymphomas, myelomas, and stem cell  transplantation, the program will showcase cutting-edge research,  clinical insights, and bold new perspectives. More than a series  of lectures, this gathering is designed to cultivate dialogue  between seasoned experts and emerging thought leaders.

Networking

Connect with global experts and peers in an intimate setting.

Mentorship

Guidance from established leaders to shape future careers.

Innovation

Exploring new therapies and breakthrough research.

Participation in this event is reserved for invited healthcare professionals and sponsoring partners who share a commitment to advancing hematology through collaboration, mentorship, and innovation. Beyond the scientific sessions, attendees will find unparalleled opportunities for networking, knowledge-sharing, and mentorship, all in a collegial environment that fosters discovery and leadership development.

Why attend

This summit strengthens collaboration and empowers the next generation of leaders in hematology.

Exchange ideas with established leaders and rising voices

Access cutting-edge clinical research and insights

Build meaningful, long-term connections

Engage in mentorship opportunities

Contribute to faster progress for patients worldwide

Chairs

Naval Daver, MD
MD Anderson Cancer Center Houston, Texas

"Our focus is to collaborate, spark new trials and treatments, and turn ideas into clinical progress. Join us in shaping the future of hematology."

Elias Jabbour, MD
MD Anderson Cancer Center Houston, Texas

"This meeting is a key forum to share ideas, present new research, and connect with our community as we celebrate progress each year."

Program Agenda

Two-day program focused on leukemias and targeted therapies.
Session 1
MDS Updates & Case Discussions
15min - Each talk/case
45min - Panel discussion
Updates in frontline HR MDS management and future directions
Dr Garcia-Manero
Updates in LR MDS management and upcoming drugs
Rami Komrokji
MDS case based discussion
Yasmin Abaza
Session 2
Chronic Leukemia
15min - Each talk/case
45min - Panel discussion
Frontline CML Updates and Future directions
Elias Jabbour
R/R CML: Current approach 2026
Guss Issa
Management of PV, ET, prefibrotic MF: Emerging strategies
Prithviraj Bose
Management of frontline MF: Focus on Combinations
John Mascarenhas
Case presentation 1 MPN: Fellow/Junior faculty
Fadi Haddad
CLL: How to optimally incorporate BTK inhibitors in the treatment of CLL
Nitin Jain
Treatment of R/R CLL
Matt Davids
Case Presentation 2 CLL: Junior faculty
Mahesh Swaminathan
Panel discussion
Elias Jabbour
Naval Daver
Session 3
Targeted Therapies in AML - The move towards combinations
15min - Each talk/case
10min - Each debate presenter
30min - Panel discussion
FLT3-inhibitors in AML: Frontline approaches in young and old AML
Alexander Perl
Using FLT3 MRD to guide treatment decisions in FLT3-mutated AML
Chirs Hourigan
Debate: NGS based MRD should be the key factor determining alloSCT vs no alloSCT in frontline FLT3m AML
PRO Yasmin Abaza
CON Jayastu Senapati
How do we envision using Frontline menin inhibitors:
Ongoing trials and data
Joshua Zeidner
Are all Menin inhibitors made equal: Mechanisms of resistance and selecting the best menin inhibitor for use
Eunice Wang
Panel discussion
All speakers
Session 4
Optimizing frontline therapy in ALL
How I treat Ph-positive ALL
N Short
Optimizing Ph-negative frontline therapy
Elias Jabbour
Older ALL, How to treat
TBD
How to tailor therapy according to MRD
Aaron Logan
Session 5
Future directions in AML Therapy
15min - Each talk/case
30min - Panel discussion
FLT3-like signature and FLT3 microclones: The QuANTUM-Wild story
Jessica Altman
CD123 and CD33 targeting in AML: Moving from bench to bedside
David Sallman
MRD as an endpoint and MRD based therapies in AML: Myth or Reality
Tapan Kadia
Case discussion: Sequential Targeted Therapy in AML patient
Sankalp Arora
Panel discussion
All speakers
Session 6
Optimizing outcomes of patients with R-R ALL
15min - Each talk/case
10min Each debate presenter
30min - Panel discussion
Novel agents in R-R ALL
Ibrahim Aldoss
Is Transplant always needed in CR2?
Roberta Azevedo
Debate: CAR-T as definitive therapy or a bridge to allo-SCT
PRO: Finite Jae Park
CON: Bridge Bijal Shah
How to sequence options: case based discussion
Hannah Goulart
Session 7
Optimizing Frontline AML – Uses of Venetoclax
15min - Each talk/case
10min - Each debate presenter
30min - Panel discussion
The “ideal” approach to molecularly classifying frontline AML in a busy clinical practice
S Loghavi
Incorporating Venetoclax into frontline IC regimens: Still a research question or primetime now?
C DiNardo
The PARADIGM study: Practical guidance for real world application of this data
Amir Fathi
Debate: Use of venetoclax based triplet vs doublet in frontline FLT3-ITD mutated AML not suitable for IC
PRO Hannah Goulart
CON Hima Atluri
Improving conditioning by incorporating VEN into pre. alloSCT conditioning
Uday Popat
Panel discussion
All speakers
Session 8
ALL Personalized therapy
T-cell ALL, ETP, and near ETP
TBD
Ph-like ALL
Sara Taisan
Genomic Classification of ALL
TBD
Myeloid mutations in ALL: a new entity
Koichi Takahashi

Partnership Opportunities

A selective platform for industry partners to connect with established thought leaders and future innovators.
Visionary partner
10 conference passes
Pre-conference faculty roundtable lunch
45-minute corporate symposium (breakfast or lunch)
Individual faculty engagement opportunities
Premium exhibitor space
Private hospitality suite
Bag inserts, key card branding
Logo and banner in email outreach
Request Details
Innovative partner
7 conference passes
30-minute corporate symposium
Individual faculty engagement
Exhibitor table
Bag insert
Prominent logo display on event platform and onsite signage
Request Details
Collaboration partner
5 conference passes
30-minute corporate symposium
Faculty engagement opportunities
Bag insert
Recognition in conference materials and networking sessions
Request Details
Supporting partner
3 conference passes
30-minute corporate symposium
Recognition in conference materials and networking sessions
Request Details

Additional Opportunities

Meet & Greet
Casual networking in an exclusive setting.
  • Up to 10 clinical participants
  • 2–3 hour networking session
  • Hosted at offsite venue
  • Full event coordination
Conference Backpack
Exclusive sponsorship of official  attendee backpack.
  • Company logo on all backpacks
  • Option to insert branded item
Congress Lanyards
Exclusive to one sponsor.
  • Logo on all lanyards
  • Optional QR code linking to website
Exhibition Stand
 3 × 3 meter branded booth.
  • Draped table & chairs
  • Logo identification signage
  • Two conference badges
Charging Kiosks
Convenient charging with brand visibility.
  • LCD display for branding
  • 7–12 min. engagement per charge
Wi-Fi Sponsorship
Exclusive official conference Wi-Fi  network branding.
  • Company name on Wi-Fi network
  • Visibility throughout event

Contact & registration

Contact
For all registration and sponsorship inquiries, contact us at:
Email
info@thekolnetwork.com
Venue
Denver, Colorado
"This summit strengthens collaboration and empowers the next generation of leaders in hematology."
Registration form
Participation is reserved for invited healthcare professionals and sponsors.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.